By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Karyopharm Therapeutics 

Newton  Massachusetts    U.S.A.
Phone: n/a Fax: n/a



Company News
Karyopharm Therapeutics (KPTI) Announces Full Exercise Of Underwriters Option To Purchase Additional Shares In Public Offering Of Common Stock 6/30/2014 7:44:47 AM
Karyopharm Therapeutics (KPTI) Announces Pricing Of Public Offering of Common Stock 6/27/2014 7:24:26 AM
Karyopharm Therapeutics (KPTI) Announces Proposed Public Offering Of Common Stock 6/26/2014 7:40:39 AM
Karyopharm Therapeutics (KPTI) Initiates Registration-Directed, Randomized Study Of Selinexor (KPT-330) In Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) 6/24/2014 9:00:59 AM
Veristat, Inc. And Karyopharm Therapeutics (KPTI) Enter Into Preferred Provider Agreement For Oncology And Novel Therapeutic Advancement 6/16/2014 10:27:53 AM
Karyopharm Therapeutics (KPTI) Announces: FDA Considers The Effectiveness And Safety Technical Sections Complete To Support Conditional Approval For The New Animal Drug Application For Verdinexor (KPT-335) To Treat Lymphoma In Client Owned Dogs 6/16/2014 7:35:25 AM
Karyopharm Therapeutics (KPTI) Announces First Combination Data Of Selinexor With Low-Dose Dexamethasone In Heavily Pretreated Multiple Myeloma Patients 6/13/2014 8:14:08 AM
Karyopharm Therapeutics (KPTI) Announces Initiation Of Phase 2 Study Of Selinexor (KPT-330) In Patients With Hormone Refractory Prostate Cancer (SHIP Study) 6/9/2014 9:22:33 AM
Karyopharm Therapeutics (KPTI) Provides Data Update For Selinexor In Non-Hodgkin's Lymphoma And Acute Myeloid Leukemia At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014 9:40:58 AM
Karyopharm Therapeutics (KPTI) Updates Data For Selinexor In Solid Tumors At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014 9:16:07 AM